Expert Discusses Excitement for Immunotherapy Potential in Ovarian Cancer – Targeted Oncology
Targeted Oncology |
Expert Discusses Excitement for Immunotherapy Potential in Ovarian Cancer
Targeted Oncology Results of the phase III JAVELIN 200 Ovarian trial have the potential to make a practice-changing impact on the field of ovarian cancer, according to Bradley J. Monk, MD, as immunotherapy could finally make its mark on management of this disease. |
